Trial Profile
Human Papillomavirus Antibody Response After GARDASIL 9 Vaccination in Patients After Allogeneic Stem Cell Transplantation
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs V 503 (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- 29 Jun 2023 Planned End Date changed from 31 May 2023 to 31 May 2024.
- 29 Jun 2023 Planned primary completion date changed from 31 May 2023 to 31 May 2024.
- 29 Jun 2022 Planned primary completion date changed from 31 May 2022 to 31 May 2023.